Media coverage about Bioblast Pharma (NASDAQ:ORPN) has been trending somewhat positive this week, Accern Sentiment Analysis reports. The research firm scores the sentiment of press coverage by reviewing more than twenty million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Bioblast Pharma earned a news sentiment score of 0.11 on Accern’s scale. Accern also assigned news coverage about the biopharmaceutical company an impact score of 45.270760825623 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.
Separately, ValuEngine upgraded shares of Bioblast Pharma from a “strong sell” rating to a “sell” rating in a research report on Tuesday, September 26th.
Bioblast Pharma (NASDAQ:ORPN) opened at $2.40 on Tuesday. Bioblast Pharma has a 1 year low of $1.49 and a 1 year high of $7.75. The stock has a market cap of $8.02, a price-to-earnings ratio of -0.93 and a beta of -0.05.
Bioblast Pharma Ltd (BioBlast) is an Israel-based development-stage biopharmaceutical company. The Company is focused on the identification, licensing, acquisition, development and commercialization of drugs for rare and ultra-rare genetic and metabolic diseases. It focuses on therapeutic platforms that offer solutions for several diseases that share a common pathophysiological mechanism, which are the functional changes that accompany a particular syndrome or disease.
Receive News & Ratings for Bioblast Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bioblast Pharma and related companies with MarketBeat.com's FREE daily email newsletter.